But the country’s second-largest pathology group cannot say what assets are being considered for sale after it recorded a collapse in margins since June 30.
There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.